![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
October 13, 2022
This phase 3 study aims to explore whether treatment with a TKI plus blinatumomab may be superior to the usual treatment approach for acute lymphoblastic leukemia
August 16, 2022
Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation
August 16, 2022
This phase 3 study is using PET/CT imaging to guide treatment for patients with post-prostatectomy biochemical recurrence
June 21, 2022
This single-arm phase 2 study aims to rid patients of residual disease following initial treatment
April 15, 2022
The ground-breaking NCI-MATCH precision medicine cancer trial continues to offer treatment opportunities for adult patients with relapsed, refractory cancers. Lead investigators Nilo Azad, MD, and April Salama, MD, discuss Arms Z1M and H.
April 15, 2022
In an enormous undertaking, ECOG-ACRIN and the NCI have built the knowledge base and infrastructure for future precision medicine trials. The new Genomics Subcommittee is offering expertise moving forward.
April 15, 2022
This study aims to determine if it is safe to omit adjuvant chemotherapy after surgery for patients with pathologic complete response (pCR) after 12 weeks of pre-operative treatment
February 24, 2022
ECOG-ACRIN is leading the first randomized trial evaluating treatment strategies for patients with combined hepatocellular carcinoma-cholangiocarcinoma
January 26, 2022
This phase 2/3 study is exploring new treatment approaches for patients with recurrent and metastatic head and neck squamous cell carcinoma
January 26, 2022
This randomized phase 2 trial aims to establish which agent, infliximab versus intravenous immunoglobulin, may lead to greatest benefit as pneumonitis treatment for patients receiving PD-1/PD-L1 therapy
December 22, 2021
This observational study aims to assess the effects of the pandemic as a barrier to enrollment in the TMIST breast cancer screening trial
December 22, 2021
This trial aims to help define the optimal first-line treatment for patients with advanced, EGFR-mutant NSCLC and elucidate mechanisms of resistance to therapy